What insurance policy changes affect HCPCS J9190?

There are 6 tracked policy changes affecting HCPCS J9190, including updates from Aetna, Highmark. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9190?

Payers that have issued tracked updates for HCPCS J9190 include: Aetna, Highmark.

How do I get notified when HCPCS J9190 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9190. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9190?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9190 Insurance Policy Changes

HCPCS J9190 is officially defined as "Injection, fluorouracil, 500 mg." HCPCS J9190 is referenced in 6 tracked payer policy changes from Aetna and Highmark. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9190 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Glaucoma Surgery (CPB 0484, reviewed 2026-07-14)
Aetna·Effective Jul 14, 2026
Aetna has updated its Glaucoma Surgery clinical policy (CPB 0484, effective 2026-07-14) clarifying coverage for multiple surgical techniques including laser trabeculoplasty, FDA-approved shunt implants, micro-bypass stents (iStent, Hydrus), XEN system, and goniotomy/trabeculotomy procedures. The policy establishes specific medical necessity criteria, contraindications, and experimental/investigational determinations that will affect billing, prior authorization requirements, and claim adjudication for glaucoma surgeries.
High impact
Ramucirumab (Cyramza) (CPB 0883, reviewed 2026-06-03)
Aetna·Effective Jun 3, 2026
Aetna updated its Ramucirumab (Cyramza) clinical policy effective June 3, 2026, expanding coverage criteria for multiple cancer indications including gastric, NSCLC, colorectal, hepatocellular carcinoma, mesothelioma, and thymic carcinoma. All ramucirumab administration now requires mandatory precertification before treatment begins. Billing teams must implement precertification workflows and verify dosing compliance with FDA-approved labeling.
High impact
Prior Authorization Changes to Oncology-related Codes
Highmark·Effective May 1, 2026
Effective May 1, 2026, Highmark is adding 115 oncology-related codes to their prior authorization requirement list, including common chemotherapy medications and radiation therapy procedures. All authorization requests for these codes must be submitted electronically through Availity Essentials and will be reviewed by Evolent as part of Highmark's oncology value-based care strategy.
High impact
Irinotecan Liposome Injection (Onivyde) (CPB 0902, reviewed 2026-02-24)
Aetna·Effective Feb 24, 2026
Aetna has updated its coverage policy for Irinotecan Liposome Injection (Onivyde) effective immediately, establishing specific medical necessity criteria for ampullary adenocarcinoma and pancreatic adenocarcinoma treatments. The policy defines approved indications including first-line NALIRIFOX regimens, subsequent therapy scenarios, and dosing requirements, while designating all other uses as experimental/investigational. Billing teams must verify patient diagnoses, treatment lines, prior therapy history, and performance status documentation before processing claims for HCPCS code J9205.
High impact
Panitumumab (Vectibix) (CPB 0748, reviewed 2025-12-23)
Aetna·Effective Dec 23, 2025
Aetna has updated its panitumumab (Vectibix) clinical policy (CPB 0748) effective 2025-12-23, establishing new coverage criteria for colorectal cancer treatment. The policy now requires RAS mutation testing (wild-type status), mandates precertification for all requests, and specifies strict combination therapy requirements including left-sided tumor limitation for first-line colon cancer and mandatory encorafenib combination for BRAF V600E mutations. All other indications remain experimental/investigational.
High impact
Levoleucovorin (Khapzory) (CPB 0889, reviewed 2025-12-04)
Aetna·Effective Dec 4, 2025
Aetna is implementing a cost-containment policy for Levoleucovorin (Khapzory) that requires precertification for all commercial medical plan members. Khapzory is now considered medically necessary only when leucovorin is unavailable or when members have a contraindication, intolerance, or ineffective response to generic levoleucovorin. Generic levoleucovorin is now the preferred first-line option for all three approved indications.

All billing codes J3590 99213 99214 99212 99203 99202

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Glaucoma Surgery (CPB 0484, reviewed 2026-07-14)

Ramucirumab (Cyramza) (CPB 0883, reviewed 2026-06-03)

Prior Authorization Changes to Oncology-related Codes

Irinotecan Liposome Injection (Onivyde) (CPB 0902, reviewed 2026-02-24)

Panitumumab (Vectibix) (CPB 0748, reviewed 2025-12-23)

Levoleucovorin (Khapzory) (CPB 0889, reviewed 2025-12-04)